How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Pharma and Healthcare · Forecast 2027–2033
Human Vaccines Market
- By Vaccine Type: Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines, Toxoid Vaccines, mRNA Vaccines, Viral Vector Vaccines
- By Disease Indication: Influenza, Hepatitis B, Human Papillomavirus (HPV), Measles, Mumps, and Rubella (MMR), Pneumococcal Disease, COVID-19
- By Age Group: Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines, Geriatric Vaccines
- By End User: Hospitals, Clinics and Physician Offices, Public Health Programs, Pharmacies, Travel Clinics
- By Technology Platform: Recombinant DNA Technology, mRNA Technology, Viral Vector Technology, Conjugate Technology, Protein Subunit Technology
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Projected to reach $X,XXX.XM by 2033 on sustained demand. Market Outlook →
- 03 Growth - X.XX% CAGR across 2027–2033, with the full year-by-year model inside. Market Outlook →
- 04 Leading segment - Live Attenuated Vaccines leads By Vaccine Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 310 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.186 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.194 →
Full report · locked preview
Everything inside the Human Vaccines Market report
A complete, evidence-based study - 12 chapters and 130 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Vaccine Type 6
Disease Indication 6
Age Group 4
End User 5
Technology Platform 5
Companies profiled
Pfizer Inc.
GlaxoSmithKline plc (GSK)
Sanofi S.A.
Merck & Co. Inc.
Johnson & Johnson
AstraZeneca plc
Bharat Biotech International Ltd.
Serum Institute of India Pvt. Ltd.
Novavax Inc.
Baxter International Inc.
Sinovac Biotech Ltd.
CureVac N.V.
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Pfizer Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →GlaxoSmithKline plc (GSK)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Sanofi S.A.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Merck & Co. Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Johnson & Johnson
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →AstraZeneca plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Bharat Biotech International Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Serum Institute of India Pvt. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Novavax Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Baxter International Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Sinovac Biotech Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →CureVac N.V.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Valneva SE
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Becton
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Dickinson and Company
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Takeda Pharmaceutical Company Limited
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →
Global · 2025–2033
$4,442M by 2033 · 8.0% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Live Attenuated Vaccines43.7
- Inactivated Vaccines17.6
- Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines7.3
- Toxoid Vaccines7.0
- mRNA Vaccines9.9
- Viral Vector Vaccines14.4
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$789.2M → $1,351M · 7.0%
Europe$550.1M → $933.0M · 6.8%
Asia Pacific$502.2M → $858.6M · 6.9%
Latin America$310.9M → $605.2M · 8.7%
Middle East and Africa$239.2M → $410.1M · 7.0%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →7.992026
8.002027
8.032028
8.042029
8.042030
8.062031
8.072032
8.072033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Pfizer Inc.18.4
- GlaxoSmithKline plc (GSK)22.5
- Sanofi S.A.5.4
- Merck & Co. Inc.6.1
- Johnson & Johnson8.9
- AstraZeneca plc10.7
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Vaccine Type22.4%
Disease Indication22.1%
Age Group7.7%
End User22.4%
Technology Platform25.4%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.5
- Europe22.4
- Asia Pacific20.6
- Latin America14.6
- Middle East and Africa9.9
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Pfizer Inc. | 97 | 90 | 87 | 78 | 82 | 96 | 88 |
| GlaxoSmithKline plc (GSK) | 73 | 69 | 91 | 84 | 84 | 89 | 82 |
| Sanofi S.A. | 64 | 75 | 67 | 85 | 82 | 79 | 75 |
| Merck & Co. Inc. | 66 | 75 | 78 | 70 | 63 | 78 | 72 |
| Johnson & Johnson | 72 | 66 | 58 | 60 | 52 | 74 | 64 |
| AstraZeneca plc | 50 | 68 | 63 | 48 | 57 | 49 | 56 |
| Bharat Biotech International Ltd. | 48 | 41 | 52 | 57 | 55 | 55 | 51 |
| Serum Institute of India Pvt. Ltd. | 41 | 48 | 39 | 57 | 54 | 54 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Pfizer Inc.
- GlaxoSmithKline plc (GSK)
- Sanofi S.A.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Pfizer Inc. | ✓ | ✓ | ✓ | ◐ | ◐ | ✓ |
| GlaxoSmithKline plc (GSK) | ◐ | ◐ | ✓ | ✓ | ✓ | ✓ |
| Sanofi S.A. | ◐ | ◐ | − | ✓ | ◐ | ✓ |
| Merck & Co. Inc. | − | ✓ | ✓ | ◐ | − | ◐ |
| Johnson & Johnson | ◐ | − | ◐ | − | ◐ | ◐ |
| AstraZeneca plc | − | ✓ | ◐ | ◐ | ◐ | − |
| Bharat Biotech International Ltd. | ◐ | − | − | − | − | − |
| Serum Institute of India Pvt. Ltd. | − | ◐ | − | − | ◐ | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Pfizer Inc.88
2GlaxoSmithKline plc (GSK)82
3Sanofi S.A.75
4Merck & Co. Inc.72
5Johnson & Johnson64
6AstraZeneca plc56
7Bharat Biotech International Ltd.51
8Serum Institute of India Pvt. Ltd.49
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Pfizer Inc.GlaxoSmithKline plc (GSK)
Challenger2
Strong scale, closing on the leaders.
Sanofi S.A.Merck & Co. Inc.
Contender1
Focused players with pockets of strength.
Johnson & Johnson
Niche3
Specialists in a single segment or region.
AstraZeneca plcBharat Biotech International Ltd.Serum Institute of India Pvt. Ltd.
Go-to-market strategy
Land Vaccine Type in North America, then scale across Human Vaccines Market — a $493M beachhead inside a $8.40B market.
Beachhead (SOM)$493Mobtainable near-term
Serviceable (SAM)$3.27Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Live Attenuated Vaccines
Best fit — highest urgency & budget in Vaccine Type.
Economic buyer80 fit
Inactivated Vaccines
Strong fit — clear ROI and a fast path to value.
End user68 fit
Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Vaccine Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Disease Indication & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Age Group
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel30%
Digital / self-serve18%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Vaccine Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Human Vaccines Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified43%
Sales qualified24%
Evaluation11%
Closed-won6%
$16.9KCAC
$91KLTV
5.4:1LTV : CAC
< 4 moCAC payback
Investment thesis
Human Vaccines Market is a resilient opportunity — $1.07B by 2033, compounding at 4.9%.
TAM · 2025$731Mtoday
TAM · 2033$1.07Bforecast
CAGR4.9%2027–2033
Cumulative$8.02Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$1.07BTotal addressable market
SAM$438MServiceable available market
SOM$80MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.9% CAGR
Demand compounds through 2033, outpacing GDP across Vaccine Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Vaccine Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$1.07BLarge & growingTAM by 2033 at 4.9% CAGR
$438MServiceable nowreachable with today’s model
$80MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$834MBear3.2% CAGR
$1.07BBase4.9% CAGR
$1.37BBull6.4% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Disease Indication optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Human Vaccines Market — a $7.68B market by 2033. Plan: grow share from 8.2% to 17.8%.
Market size · 2033$7.68Btotal addressable
Market CAGR9.5%2027–2033
Target share17.8%from 8.2% today
Revenue ambition$1.37Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.2% | 17.8% | On track |
| Revenue | $623M | $1.37B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 35.9% | 40.9% | On track |
| Customer retention | 84.1% | 97.0% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Vaccine Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Disease Indication capability
A defensible second engine — invest in Disease Indication to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Vaccine Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Disease Indication
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $194M capacity & capability investment
- Greenlight bolt-on M&A in Disease Indication
- Authorise North America expansion plan
- Fund R&D program for Vaccine Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAt risk
- Input-cost & supply riskAhead
- Regulatory / policy changeAt risk
- Execution & talentOn track
Sales deck · value proposition
Win the Human Vaccines Market conversation — a $3.79B market you can size, segment and defend in minutes.
Market size · 2033$3.79Btotal opportunity
Growth9.4%CAGR to 2033
Addressable buyers1,515+accounts in scope
Typical ROI4.4×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Vaccine Type
Goal Grow share in Vaccine Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.4×return on cost, year one
< 2 mopayback period
$98K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Pfizer Inc.GlaxoSmithKline plc (GSK)Sanofi S.A.Merck & Co. Inc.Johnson & JohnsonAstraZeneca plcBharat Biotech International Ltd.Serum Institute of India Pvt. Ltd.+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Human Vaccines Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Human Vaccines Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Pharma and Healthcare · scroll →Contraceptive Devices Market
Market size, share, segmentation and regional forecast.
$13.4B by 2033 · 3.39% CAGR
View reportNanoemulsions Market
Market size, share, segmentation and regional forecast.
$9.5B by 2033 · 9.37% CAGR
View reportOpioid Anesthetics Market
Market size, share, segmentation and regional forecast.
$12.0B by 2032 · 10.51% CAGR
View reportBiosimilar Monoclonal Antibodies Market
Market size, share, segmentation and regional forecast.
$4.9B by 2033 · 9.38% CAGR
View reportAnti-Retroviral Drugs Market
Market size, share, segmentation and regional forecast.
$8.1B by 2032 · 4.78% CAGR
View reportBone Morphogenetic Proteins Market
Market size, share, segmentation and regional forecast.
$12.5B by 2032 · 5.03% CAGR
View reportCellulite Treatment Market
Market size, share, segmentation and regional forecast.
$7.6B by 2033 · 10.27% CAGR
View reportOral Anti-Diabetic Drug Market
Market size, share, segmentation and regional forecast.
$10.1B by 2031 · 10.30% CAGR
View reportCutaneous Fribrosis Treatment Market
Market size, share, segmentation and regional forecast.
$9.5B by 2031 · 6.87% CAGR
View reportSaline Laxatives Market
Market size, share, segmentation and regional forecast.
$2.0B by 2032 · 7.36% CAGR
View reportNebulizers Market
Market size, share, segmentation and regional forecast.
$3.9B by 2032 · 7.40% CAGR
View reportOxytocic Pharmaceuticals Market
Market size, share, segmentation and regional forecast.
$9.3B by 2032 · 9.95% CAGR
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report ships as a formatted PDF, a fully editable XLSX containing all underlying data tables, and a presentation-ready PPT deck - so you can re-chart, re-model, or drop any figure straight into your own deck.